Close Menu
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Jakarta ReporterJakarta Reporter
    • Home
    • Contact Us
    Jakarta ReporterJakarta Reporter
    Home » Prostate cancer breakthrough: Russia develops first theranostic dual drug
    Health

    Prostate cancer breakthrough: Russia develops first theranostic dual drug

    March 14, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Scientists at Tomsk Polytechnic University (TPU) have developed and patented Russia’s first theranostic pair original radiopharmaceuticals designed for both the diagnosis and treatment of prostate cancer. According to the TPU press service, the initial phase of pilot clinical trials has been successfully completed, marking a significant advancement in Russian oncology research.

    The development is part of a growing field known as theranostics, which combines diagnostic and therapeutic applications into a single approach to cancer treatment. Until now, only two theranostic molecules have been available globally, both developed by foreign companies, targeting neuroendocrine tumors and prostate cancer.

    The Tomsk scientists‘ achievement establishes Russia’s first domestically developed alternative in this field. Roman Zelchan, senior researcher at the Oncoteranostics Research Centre at TPU’s Research School of Chemical and Biomedical Technologies, emphasized the significance of this breakthrough. “We can safely say that Tomsk Polytechnic University has developed the first domestic theranostic pair,” he stated.

    Understanding theranostics: The future of cancer treatment

    Zelchan is also a leading research associate at the Department of Radionuclide Therapy and Diagnostics at the Tomsk Research Institute of Oncology, part of the Tomsk Medical Research Centre. The newly developed radiopharmaceuticals are based on the BQ-PSMA compound, enabling both diagnostic and therapeutic applications. When combined with the diagnostic radioactive isotope technetium-99m, the compound functions as a “signal beacon” that identifies tumor cells.

    The therapeutic version, incorporating lutetium-177, enhances the compound’s ability to target and destroy cancer cells effectively. Prostate cancer remains one of the most commonly diagnosed cancers worldwide, affecting approximately one in eight men during their lifetime. The introduction of this Russian theranostic technology could expand treatment options and improve outcomes for patients.

    The researchers at TPU believe their development represents a major step in advancing personalized cancer treatment within Russia and beyond. With further clinical trials and regulatory approvals, the theranostic pair could potentially become an integral part of modern oncology protocols. This breakthrough aligns with a broader push in Russia to advance domestic pharmaceutical and medical technology sectors, reducing reliance on foreign innovations. – By Eurasian Newswire News Desk.

    Related Posts

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026

    Malaria kills 22 in Namibia’s Zambezi Region as cases rise

    October 26, 2026
    Latest News

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026

    DP World partner ATI wins 25-year Manila port renewal

    November 13, 2026

    Nigeria and EU seal readmission deal after decade of talks

    November 12, 2026

    ADB flags $264 billion yearly ASEAN infrastructure gap

    November 12, 2026
    © 2026 Jakarta Reporter | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.